In summary, transcriptomic and proteomic profiles of METTLs across a broad range of cancer types and their associations with clinical outcomes indicated that a subset of METTLs, such as METTL1, METTL7B, and NTMT1, might act as oncogenes, while METTL7A acts as a tumor suppressor. This evidence concerns the gene METTL1 and cancer.